David P. Bonita - 09 Jun 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: PRLD
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:13:51 UTC
Prior SEC filing: 23 Apr 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Krishna Vaddi, Attorney-in-Fact

Filing notes and source

Key filing fact

David P. Bonita filed Form 4 for Prelude Therapeutics Inc (PRLD) on 10 Jun 2026.

Key facts

This page summarizes David P. Bonita's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 16:13.

Change

Previous filing in this sequence was filed on 23 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001572451 Primary reporting owner

Bonita David P

Relationship: Director, 10%+ Owner
Address: C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON
Signature: /s/ Krishna Vaddi, Attorney-in-Fact
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.